Correlated Drug Terms (2)

---

	Name (Synonyms)	Correlation
drug1200	Group Social ABCs Wiki	1.00
drug2828	Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Wiki	0.71

Correlated MeSH Terms (2)

---

	Name (Synonyms)	Correlation
D001321	Autistic Disorder NIH	0.38
D000067877	Autism Spectrum Disorder NIH	0.33

Correlated HPO Terms (2)

---

	Name (Synonyms)	Correlation
HP:0000717	Autism HPO	0.38
HP:0000729	Autistic behavior HPO	0.33

Primary Outcomes

Description: Tests based on detection of the virus SARS-CoV-2 (antigenic rapid tests, molecular tests, proteomic tests): sensibility and specificity compared to RT-PCR (Ct) in salivary samples and nasopharyngeal swabs from patients and cargivers included in the study Tests based on detection of human antibodies generated in response to infection (rapid immunodiagnostic tests, ELISA): sensibility and specificity compared to RT-PCR (Ct) and ELISA (antibody titer) in blood or serum from patients and cargivers included in the study

Measure: Clinical performance of several diagnostic tests : tests based either on detection of the virus SARS-CoV-2 or detection of human antibodies generated in response to infection

Time: Total duration of the study is 10 months

---

Secondary Outcomes

Description: Hospitalized patients, positive or suspected of SARS-CoV-2 infection are included in the study. Medical data related to COVID-19 infection will be recorded. Caregivers will be asked information about their health status related to a possible COVID-19 infection: symptoms if any, symptoms duration, severity.

Measure: Sensitivity and specificity of immunological, antigenic, molecular and proteomic tests according to symptom duration, stage of the disease: asymptomatic, ambulatory, hospitalized, ventilated

Time: Total duration of the study is 10 months

---

Description: At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.

Measure: Description of the incidence of infection among hospital caregivers, time to seroconversion according to clinical form, medium-term antibody persistence

Time: Caregivers will be included in the study for 9 months. After inclusion (Day 0), follow-up visits at Day 15, 1 Month, 3 Months, 6 Months, 9 Months will be done.

---

Description: Blood samples (capillary and venous) will be taken for serology testing from hospitalized patients, positive or suspected of SARS-CoV-2 infection and from hospital caregivers exposed to SARS-CoV-2. Participants will be asked information about their health status and medical data related to COVID-19 infection will be recorded.

Measure: Sensitivity and specificity of immunodiagnostic tests according to the sample used (serum and capillary blood) and according to the duration of the symptoms

Time: Total duration of the study is 10 months

---

Description: Blood samples (capillary and venous) will be taken for serology testing from hospitalized patients, positive or suspected of SARS-CoV-2 infection and from hospital caregivers exposed to SARS-CoV-2. Participants will be asked information about their health status and medical data related to COVID-19 infection will be recorded.

Measure: Sensitivity and specificity of antigenic rapid tests, molecular tests, proteomic tests according to the sample used (salivary samples or nasopharyngeal swabs) and according to the duration of the symptoms

Time: Total duration of the study is 10 months

---

Description: Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.

Measure: Suitability of rapid tests in view of its intended purpose for self-testing

Time: 4 months

---